Initiator Explores Unmet Need In Erectile Dysfunction Space

It is over 25 years since the US Food and Drug Administration gave the green light to Pfizer Inc.‘s Viagra, followed by approvals for other phosphodiesterase type 5 (PDE5) inhibitors, notably Eli Lilly’s Cialis, and while they have proved highly effective in treating erectile dysfunction (ED), there is still a considerable unmet need.

So says Claus Elsborg Olesen, CEO of Initiator Pharma A/S, which has recently presented positive initial findings from a Phase IIb study of pudafensine, an oral treatment that is...